LISINOPRIL AND HYDROCHLOROTHIAZIDE AMILORIDE - A COMPARATIVE-STUDY IN THE TREATMENT OF PATIENTS WITH MILD-TO-MODERATE HYPERTENSION

This Canadian multicenter study involving 14 investigators and 185 patients compared the efficacy and safety of lisinopril with hydrochlorothiazide (HCTZ)/amiloride in the treatment of mild-to-moderate essential hypertension, This double-blind, controlled, randomized, parallel-design study lasted 12 weeks; it was preceded by a placebo period of 2 to 4 weeks to establish a baseline for each patient. The titration period was followed by a maintenance period of 4 to 8 weeks. Patients with a supine diastolic blood pressure (DBP) greater than or equal to 95 and less than or equal to 114 mm Hg were eligible for entry into the study. The primary goals for blood pressure control were a supine DBP <90 mm Hg and a decrease in supine DBP of >10 mm Hg from baseline. Results of this study demonstrate that (1) lisinopril and HCTZ/amiloride effectively reduce systolic blood pressure (SEP) and DBP in both the supine and standing positions; (2) the mean reductions of SEP and DBP are greater with lisinopril than with HCTZ/amiloride; (3) supine DBP <90 mm Hg is achieved more often with lisinopril; (4) reduction of supine DBP of >10 mm Hg is achieved more often with lisinopril; (5) both lisinopril and HCTZ/amiloride are well tolerated; and (6) the incidence of adverse laboratory results is minimal with both treatments but occurs less frequently with lisinopril.